Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer

被引：48

作者：

Collins, TS ^{[1
]}

Hurwitz, HI ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC 27710 USA

来源：

SEMINARS IN ONCOLOGY | 2005年 / 32卷 / 01期

关键词：

D O I：

10.1053/j.seminoncol.2004.09.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis, the development and proliferation of new blood vessels, is critical for the growth of tumors. The process of new blood vessel formation is under complex control from a variety of pro- and anti-angiogenesis factors. By identifying and understanding these factors, new therapies have been developed to inhibit tumor growth and survival by blocking tumor-related angiogenesis. Recent success with the monoclonal antibody against vascular endothelial growth factor (VEGF; bevacizumab) in a large, randomized, phase III study has provided a critical proof of principle for this therapeutic area. This review will outline the biology of angiogenesis in colorectal cancer and discuss the current status of angiogenesis inhibition in its treatment. © 2005 Elsevier Inc. All rights reserved.

引用

页码：61 / 68

页数：8

共 95 条

[41] SYNTHETIC ANALOGS OF FUMAGILLIN THAT INHIBIT ANGIOGENESIS AND SUPPRESS TUMOR-GROWTH [J].

INGBER, D ;

FUJITA, T ;

KISHIMOTO, S ;

SUDO, K ;

KANAMARU, T ;

BREM, H ;

FOLKMAN, J .

NATURE, 1990, 348 (6301) :555-557

[42]

Joukov V, 1996, EMBO J, V15, P290

[43] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J].

Kabbinavar, F ;

Hurwitz, HI ;

Fehrenbacher, L ;

Meropol, NJ ;

Novotny, WF ;

Lieberman, G ;

Griffing, S ;

Bergsland, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :60-65

[44] The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells [J].

Kanthou, C ;

Tozer, GM .

BLOOD, 2002, 99 (06) :2060-2069

[45] VASCULAR-PERMEABILITY FACTOR, AN ENDOTHELIAL-CELL MITOGEN RELATED TO PDGF [J].

KECK, PJ ;

HAUSER, SD ;

KRIVI, G ;

SANZO, K ;

WARREN, T ;

FEDER, J ;

CONNOLLY, DT .

SCIENCE, 1989, 246 (4935) :1309-1312

[46] INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO [J].

KIM, KJ ;

LI, B ;

WINER, J ;

ARMANINI, M ;

GILLETT, N ;

PHILLIPS, HS ;

FERRARA, N .

NATURE, 1993, 362 (6423) :841-844

[47]

KOEPPEN HKW, 2004, 16 EORTC NCI AACR S

[48] Recent experience with oxaliplatin or irinotecan combined with S-fluorouracil and leucovorin in the treatment of colorectal cancer [J].

Kuebler, JP ;

de Gramont, A .

SEMINARS IN ONCOLOGY, 2003, 30 (04) :40-46

[49] VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A SECRETED ANGIOGENIC MITOGEN [J].

LEUNG, DW ;

CACHIANES, G ;

KUANG, WJ ;

GOEDDEL, DV ;

FERRARA, N .

SCIENCE, 1989, 246 (4935) :1306-1309

[50]

LIAW CC, 1993, CANCER, V72, P1382, DOI 10.1002/1097-0142(19930815)72:4<1382::AID-CNCR2820720438>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →